Loading...
•
Dec 31, 2025
Royalty Pharma Q4 2025 Earnings Report
Royalty Pharma reported strong fourth quarter 2025 results with double-digit growth in Portfolio Receipts and Royalty Receipts.
Key Takeaways
Royalty Pharma generated Portfolio Receipts of 874000000 in Q4 2025, up 18%, with Royalty Receipts of 856000000 and net income attributable to Royalty Pharma plc of 214000000.
Portfolio Receipts increased 18% to 874000000 in Q4 2025.
Royalty Receipts grew 17% to 856000000.
Adjusted EBITDA reached 816000000, up 22%.
Net cash provided by operating activities was 827000000.
Revenue by Segment
Forward Guidance
For full year 2026, Royalty Pharma expects Portfolio Receipts between 3275000000 and 3425000000, including Royalty Receipts growth of 3% to 8%.
Positive Outlook
- 2026 Portfolio Receipts guidance of 3275000000 to 3425000000.
- Expected Royalty Receipts growth of 3% to 8% in 2026.
- Operating and professional costs expected to decline as a percentage of Portfolio Receipts.
- Robust development-stage pipeline with multiple pivotal readouts in 2026.
- Strong capital allocation flexibility supported by 619000000 cash balance.
Challenges Ahead
- Guidance excludes contribution from future transactions.
- Interest payments expected between 350000000 and 360000000 in 2026.
- Exposure to foreign exchange fluctuations.
- Reliance on portfolio product performance and regulatory outcomes.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...